| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $168,063,754 ) (Continued on the next page) |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | T32CA009207 | Investigational Cancer Therapeutics Training Program (ICTTP) | 000 | 47 | NIH | 4/21/2026 | $6,000 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA301130 | Deciphering pathogenesis and therapeutic vulnerabilities in germline RUNX1 mutated AML | 000 | 2 | NIH | 8/5/2026 | $495,715 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA303470 | DLL3-targeted IL18-secreting CAR T cells in Small Cell Lung Cancer | 000 | 2 | NIH | 7/14/2026 | $730,398 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01NS126921 | Chemical Genetic Dissection of SWI/SNF Chromatin Remodeling Complex Functions in Cerebral Cortex Development | 000 | 4 | NIH | 4/2/2026 | $565,593 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08CA301011 | Genome instability associated with oncogene amplification and its therapeutic strategy | 000 | 2 | NIH | 7/6/2026 | $292,028 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA288692 | HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted ADC therapy in urothelial carcinoma | 000 | 3 | NIH | 3/3/2026 | $594,012 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R35GM158422 | Mechanisms of Lipid Droplet Protein Targeting | 000 | 2 | NIH | 5/27/2026 | $440,000 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA290400 | Investigating hypoxia as a determinant of malignant fates in pancreas cancer | 000 | 3 | NIH | 4/6/2026 | $695,124 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA258622 | Ferroptosis and Cancer Cell Signaling | 000 | 5 | NIH | 1/19/2026 | $411,339 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA258622 | Ferroptosis and Cancer Cell Signaling | 001 | 5 | NIH | 4/16/2026 | $45,703 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | P01CA291697 | Lipid Metabolism as a Determinant of Ferroptosis Sensitivity in Cancer | 000 | 2 | NIH | 7/14/2026 | $2,432,032 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA259177 | Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene. | 000 | 6 | NIH | 4/6/2026 | $538,178 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08CA279922 | Defining the role of GNAS in gastrointestinal metastasis | 000 | 4 | NIH | 3/27/2026 | $268,826 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA293974 | Practical Randomized Controlled Trial of Artificial Intelligence for Melanoma Diagnosis (PRACTA-MEL) | 001 | 2 | NIH | 6/29/2026 | $0 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA293974 | Practical Randomized Controlled Trial of Artificial Intelligence for Melanoma Diagnosis (PRACTA-MEL) | 000 | 2 | NIH | 3/3/2026 | $681,611 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA297030 | Metabolically Reprogramming Hepatic Macrophages to Conquer Immune Desert Tumors | 000 | 2 | NIH | 2/27/2026 | $145,336 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | UG1HL069315 | BMT Core - MSK | 000 | 26 | NIH | 7/22/2026 | $264,000 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01HG012103 | Deciphering the Genomics of Gene Network Regulation of T Cell and Fibroblast States in Autoimmune Inflammation | 001 | 5 | NIH | 6/19/2026 | $1,119,571 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA271287 | Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer | 001 | 5 | NIH | 6/5/2026 | $1,244,214 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U24CA285296 | ISIC-REPO; ISIC Skin Imaging Repository Enhancements for Promoting Interoperability and Utilization | 001 | 3 | NIH | 4/28/2026 | $696,147 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01MD016908 | Taxi ROADmAP (Realizing Optimization Around Diet And Physical activity) | 001 | 5 | NIH | 2/17/2026 | $71,885 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01MD016908 | Taxi ROADmAP (Realizing Optimization Around Diet And Physical activity) | 000 | 5 | NIH | 1/23/2026 | $646,946 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA300788 | Inflammatory Signaling in the Leptomeninges | 000 | 2 | NIH | 3/3/2026 | $730,398 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21CA292178 | Targeting Chromosomal Instability in the Evolution of Resistance to Matched Therapies Against Colorectal Cancer to Extend Treatment Response | 000 | 2 | NIH | 2/27/2026 | $246,840 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R35GM156454 | Decoding the Ubiquitin and Autophagy Signaling Networks | 000 | 2 | NIH | 2/19/2026 | $440,000 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA289752 | Myeloma Defining Genomic Events to Differentiate Benign and Malignant Myeloma Precursor Conditions | 003 | 3 | NIH | 6/8/2026 | $753,206 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | OT2CA301085 | eDyNAmiC (extrachromosomal DNA in Cancer) - Understanding the biology of ecDNA generation and action, and developing new ways to target these mechanisms in cancer | 001 | 1 | NIH | 8/14/2026 | $292,861 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA312279 | Repurposing HSP90 inhibitors as a new RTK condensate-directed therapy in cancer | 000 | 1 | NIH | 7/27/2026 | $577,331 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA313953 | Short-wave infrared Cerenkov imaging to better visualize targeted radiotherapy and diagnostic radiotracers | 000 | 1 | NIH | 6/19/2026 | $644,423 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA312002 | Decoding basal multipotency for histological transformation in lung cancer patients | 000 | 1 | NIH | 7/30/2026 | $752,280 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08CA308856 | Targeting Alternative Lengthening of Telomeres in Cancer | 000 | 1 | NIH | 7/20/2026 | $263,073 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21CA309323 | RECONJOINT: A Preference Elicitation Tool to Improve Shared Decision Making for Breast Reconstruction Surgery | 000 | 1 | NIH | 6/11/2026 | $457,252 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01DE035884 | Salivary Neural Development Programs Enable Adenoid Cystic Carcinoma Progression | 000 | 1 | NIH | 7/22/2026 | $769,938 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA315558 | Targeting Senescence- and Fibrosis-Associated Tumor States via Engineered Immunity | 000 | 1 | NIH | 7/24/2026 | $146,299 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08HL183856 | The Role of Zbtb1 in Normal and Clonal Hematopoiesis | 000 | 1 | NIH | 8/4/2026 | $169,020 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA304551 | MIRDsoft radiation dosimetry | 000 | 1 | NIH | 6/10/2026 | $676,849 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01AI196346 | Understanding and manipulating microbiome ecology to curb gut-borne infections. | 000 | 1 | NIH | 2/20/2026 | $3,519,992 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F31AI191721 | Role of Arid1a in NK cell development and antiviral immunity | 002 | 1 | NIH | 4/7/2026 | $0 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F31AI191721 | Role of Arid1a in NK cell development and antiviral immunity | 001 | 1 | NIH | 4/7/2026 | $46,564 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F31AI191721 | Role of Arid1a in NK cell development and antiviral immunity | 001 | 1 | NIH | 4/7/2026 | -$46,564 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F31AI191721 | Role of Arid1a in NK cell development and antiviral immunity | 000 | 1 | NIH | 4/3/2026 | $46,564 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R34HL184529 | Microbiome manipulation through oral live biotherapeutic product (LBP) for the treatment of gut acute graft-versus-host disease (GVHD) | 000 | 1 | NIH | 7/8/2026 | $281,722 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA308278 | Overcoming chronic inflammation-driven T cell quiescence in gastric adenocarcinoma | 000 | 1 | NIH | 4/6/2026 | $730,097 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA318433 | Access and Outcomes of Radioligand Therapy for US Veterans with Prostate Cancer | 000 | 1 | NIH | 8/6/2026 | $708,377 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA307864 | Precision Radiotheranostics Targeting Oncogenic Mutations | 000 | 1 | NIH | 7/15/2026 | $150,551 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R35GM161744 | Investigating histone glycation as a new dynamic epigenetic mark | 000 | 1 | NIH | 4/6/2026 | $528,000 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA315594 | Artificial intelligence-based integration of genomic and histopathologic data to improve precision cancer medicine | 000 | 1 | NIH | 7/16/2026 | $140,400 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA314714 | Understanding of mutant splicing factor-derived novel protein isoforms in clonal hematopoietic disorders and antigen presentation. | 000 | 1 | NIH | 7/7/2026 | $137,631 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA318448 | Optimization of structure-guided models of peptide presentation and T-cell receptor specificity | 000 | 1 | NIH | 8/11/2026 | $731,937 |
|
